Search

Crinecerfont

[A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently … [L51973] When administered alongside glucocorticoid replacement in patients with CAH it allows for the use of lower, physiological doses for glucocorticoid replacement, thereby reducing the risks associated

LetibotulinumtoxinA

[L42330] LetibotulinumtoxinA has been a market-leading cosmetic product in South Korea for a number of years and was subsequently approved in the European Union. … [A249920] The first aesthetic use of botulinum toxin was reported in 1989, when [onabotulinumtoxinA] (Botox) was used as a treatment for facial asymmetry resulting from iatrogenic facial nerve damage.

Sibeprenlimab

[L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628] … Sibeprenlimab is a Proliferation Inducing Ligand (APRIL) blocker.[L54633] APRIL is a member of the tumour necrosis factor superfamily that regulates and modulates activated B cells.

Tafenoquine

[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. … Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group.

Idarubicin

The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.

Eculizumab

[L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria … [L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.

Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen

ETC-588

Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes. … LUV are capable of transporting excess cholesterol from the vasculature to the liver for eventual elimination as part of the reverse lipid transport (RLT) pathway.

Veru-111

VERU-111, an investigational drug intended for various therapeutic uses, was under investigation in clinical trials NCT04842747, NCT03752099, NCT04388826, NCT04844749, NCT05008510, and NCT05079360.

Dipyrithione

[A32829] Interestingly, dipyrithione has been studied and shown to have cytotoxic and potent broad-spectrum antitumor activity, which suggests a potential basis for an anticancer drug development. … [L2611] It is currently used as a pesticide, and not used in any FDA approved drug products.